UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000025905
Receipt number R000029337
Scientific Title Multicenter study of Genome-Wide Association Study (GWAS) concerning of the efficacy of tolvaptan.
Date of disclosure of the study information 2017/02/01
Last modified on 2020/02/18 15:00:33

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Multicenter study of Genome-Wide Association Study (GWAS) concerning of the efficacy of tolvaptan.

Acronym

Effect of tolvaptan on refractory ascites.

Scientific Title

Multicenter study of Genome-Wide Association Study (GWAS) concerning of the efficacy of tolvaptan.

Scientific Title:Acronym

Effect of tolvaptan on refractory ascites.

Region

Japan


Condition

Condition

Liver cirrhosis with refractory ascites.

Classification by specialty

Medicine in general Hepato-biliary-pancreatic medicine

Classification by malignancy

Others

Genomic information

YES


Objectives

Narrative objectives1

To elucidate the gene concerning for the efficacy of tolvaptan, competitive vasopressin receptor 2 antagonist, for cirrhotic patients with reflactory ascites by using GWAS.

Basic objectives2

Others

Basic objectives -Others

Identification of genes affecting therapeutic effect of tolvaptan.

Trial characteristics_1

Exploratory

Trial characteristics_2

Pragmatic

Developmental phase



Assessment

Primary outcomes

Decrease of body weight.

Key secondary outcomes

Improvement of ascites.
Increase of urine volume.
Improvement of patient's symptom.


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification

NO

Dynamic allocation

NO

Institution consideration

Institution is not considered as adjustment factor.

Blocking

NO

Concealment

No need to know


Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Administration of tolvaptan (7.5mg/day) for a refractory ascites patients.

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1)Patients over 20 years old
2)Patients obtained written informed consent
3) Life expectancy of at least 4 weeks
4) Adequate organ function
a) Hb>= 8.0g/dL
b) neutrophil: >= 1,500/mm3
c) Platelet: >= 30,000/mm3
d) Total bilirubin:< 4.0 mg/dL
e) ALT and AST: <= within 6 folds of normal limit
f) Serum creatine: <= 2.0 mg/dL
g) Serum natrium: >= 120mEq/L

Key exclusion criteria

1) Adequate cardiac organ function
a) Patients with conjestive heart failure above NYHA class3
b) Patients with severe hypertension
2) Patients with severe and active infectious disease (exclude HBV,HCV hepatitis)
3) Patients with HIV
4) Patients taking dialysis
5) Patients with portal tumor thrombosis (Vp3 or Vp4)
6) Patients with hepatic encephalopathy
7) Patients with crutial digestive bleedings within 4 weeks
8) Patients with the following treatment
a) Systemic chemotherapy
b) Being treated with invasive surgical therapy within 4 weeks
9) Patients with oral intake difficulty
10)Patients with severe digestive diseases
11)Patients taking a tablet which would affect this clinical study
12)Pregnant woman, lactating woman, or a woman suspected of pregnancy
13)Patients with severe allergic reaction to Tolvaptan
14)Patients with drug abuse or psycological disorders
15) Patients concluded to be inappropriate to participate in this study by their physitians

Target sample size

300


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Hideto Kawaratani

Organization

Nara Medical University

Division name

The third department of internal medicine

Zip code


Address

Shijyo-cho 840, Kashihara, Nara, Japan

TEL

0744-22-3051(3415)

Email

kawara@naramed-u.ac.jp


Public contact

Name of contact person

1st name
Middle name
Last name Hideto Kawaratani

Organization

Nara Medical University

Division name

The third department of internal medicine

Zip code


Address

Shijyo-cho 840, Kashihara, Nara, Japan

TEL

0744-22-3051(3415)

Homepage URL


Email

kawara@naramed-u.ac.jp


Sponsor or person

Institute

The third department of internal medicine, Nara Medical University

Institute

Department

Personal name



Funding Source

Organization

Nagoya city University

Organization

Division

Category of Funding Organization

Local Government

Nationality of Funding Organization

Japan


Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

研究協力施設


Other administrative information

Date of disclosure of the study information

2017 Year 02 Month 01 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2017 Year 02 Month 01 Day

Date of IRB

2016 Year 12 Month 13 Day

Anticipated trial start date

2017 Year 02 Month 01 Day

Last follow-up date

2020 Year 03 Month 31 Day

Date of closure to data entry

2020 Year 03 Month 31 Day

Date trial data considered complete

2020 Year 03 Month 31 Day

Date analysis concluded

2020 Year 12 Month 31 Day


Other

Other related information



Management information

Registered date

2017 Year 01 Month 30 Day

Last modified on

2020 Year 02 Month 18 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000029337


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name